Samaritan to Highlight Oral HIV Entry Inhibitor and Novel Alzheimer's Drug At BioPartnering Europe to Seek Partnering Opportunities

LAS VEGAS, Oct. 3, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today, it will highlight the uniqueness and advantages of its oral HIV entry inhibitor, SP-01A, and its novel Alzheimer's drug, Caprospinol (SP-233), to major pharmaceutical companies around the world for out-licensing opportunities. In addition, Samaritan will seek in-licensing opportunities to market niche branded pharmaceuticals in Greece and Eastern Europe. BioPartnering Europe takes place October 8 -- 12, 2006 in London, England.

See peer reviewed journal publications for complete pipeline,

Samaritan Pharmaceuticals: "We LIV ... to Save Lives."

Samaritan Pharmaceuticals is a drug development company driven to commercialize innovative therapeutics for AIDS, Alzheimer's, Cancer and Heart disease. Samaritan, in collaboration with Georgetown University, is advancing eight promising compounds out of its pipeline of over 300 possible drug candidates, all of which have the potential to create revenue-generating opportunities.

Look at Website, Please register so we can notify you of upcoming conference calls, news and events.

The Samaritan Pharmaceuticals Inc. logo is available at


The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful.

For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2006. The company undertakes no duty to update forward-looking statements.


Contact Data